Latest News

05 November 2020

Infex Therapeutics and LifeArc announce collaboration to defeat superbugs

Infex Therapeutics has combined forces with medical research charity, LifeArc, to develop the next generation of drugs to treat serious infections caused by superbugs.

The collaboration will see Infex Therapeutics develop innovative antimicrobial compounds against LifeArc’s drug targets, in particular to tackle critical-priority Gram-negative bacteria.

Dr Peter Jackson, executive director of Infex Therapeutics, said, “We are delighted to announce this important collaboration with LifeArc, which could make a significant contribution to re-invigorating the pipeline of new products to treat drug-resistant infections.”

Katy Kettleborough, Head of Biology at LifeArc said “We are looking forward to working with Infex Therapeutics on our early discovery targets and value their expertise in this space”

It is anticipated that a number of disease targets will be progressed through the collaboration.

From our portfolio

Cerebrum Matter

Digital Healthcare Technology

Cerebrum Matter is a digital health company developing software and hardware focused on treating ...

viewview our portfolio

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200